Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The objective of this study is to assess the long-term outcomes after hospital admission with Covid-19 with respect to pulmonary function, physical capacity, imaging, quality of life and socioeconomic outcomes.
Description: Expert evaluation
Measure: Imaging of the lungs Time: 3 months after dischargeDescription: Expert evaluation
Measure: Imaging of the lungs Time: 12 months after dischargeDescription: Liter
Measure: Pulmonary function tests Time: 3 months after dischargeDescription: Liter
Measure: Pulmonary function tests Time: 12 months after dischargeDescription: Walking distance (meters) and change in oxygen saturation.
Measure: Six-minute walk test Time: Performed 3 months after dischargeDescription: Walking distance (meters) and change in oxygen saturation.
Measure: Six-minute walk test Time: Performed 12 months after dischargeDescription: 0-100 scale. The lower the score, the more disability.
Measure: Short Form-36 (SF-36) questionnaire Time: 3 months after dischargeDescription: 0-100 scale. The lower the score, the more disability.
Measure: Short Form-36 (SF-36) questionnaire Time: 12 months after dischargeDescription: 10-50 score. The higher the score, the more fatigue
Measure: Fatigue Assessment Score Time: 3 months after dischargeDescription: 10-50 score. The higher the score, the more fatigue
Measure: Fatigue Assessment Score Time: 12 months after dischargeDescription: 0-30. The lower the score, the more cognitive impairment
Measure: Cognitive sore (MOCA) Time: 3 months after dischargeDescription: 0-30. The lower the score, the more cognitive impairment
Measure: Cognitive sore (MOCA) Time: 12 months after dischargeDescription: 0-21. The higher the score, the more risk of anxiety or depression.
Measure: Hospital anxiety and Depression score (HADS) Time: 3 months after dischargeDescription: 0-21. The higher the score, the more risk of anxiety or depression.
Measure: Hospital anxiety and Depression score (HADS) Time: 12 months after dischargeDescription: Any pre-COVID-19 comorbidity and treatment with immmunosuppressants will be registered.
Measure: Comorbidities Time: 12 months after dischargeDescription: Change in outcomes between discharge and follow-up visits will be evaluated
Measure: Blood sample at routine follow up. Time: 3 months after dischargeDescription: Change in outcomes between discharge and follow-up visits will be evaluated
Measure: Blood sample at routine follow up. Time: 12 months after dischargeDescription: Knowledge regarding COVID19 is drastically evolving. Biobanking makes it possible to investigate blood samples in the future corresponding to ongoing evidence.
Measure: Biobanking of blood Time: 3 months after dischargeDescription: Knowledge regarding COVID19 is drastically evolving. Biobanking makes it possible to investigate blood samples in the future corresponding to ongoing evidence.
Measure: Biobanking of blood Time: 12 months after dischargeAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports